MRE11 Gene (MRE11A) Microcephaly Genetic Test in UAE | 2800 AED | DHA Licensed

Executive Summary & Core Metrics

Executive Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189:2022 / ISO 9001:2015 Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed Consultant Medical Geneticist.
Insurance Verification: Direct billing confirmation via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The MRE11 Genetic Test identifies pathogenic variants in the MRE11A gene associated with primary microcephaly, ataxia-telangiectasia-like disorder, and hereditary breast and ovarian cancer predisposition. Using ISO-accredited next-generation sequencing, this test delivers comprehensive molecular diagnosis to guide pediatricians, clinical geneticists, and oncologists in precision management and family counseling under UAE regulatory standards.

Feature	Our MRE11 NGS Test	Closest Alternative (Sanger / CMA)
Technology & Resolution	Full-gene NGS sequencing (Illumina) of all coding exons, intron-exon boundaries, and copy number variants (CNVs) at >100x coverage	Targeted Sanger sequencing of known hotspots; chromosomal microarray (CMA) for CNVs only – misses novel and deep intronic variants
Diagnostic Yield	Greater than 99.9% sensitivity for SNVs, indels, and CNVs in the MRE11 gene, ensuring maximal detection	Approximately 95% for known variants; up to 30% of pathogenic variants may remain undetected in atypical presentations
Turnaround Time	3–4 weeks from sample receipt via ISO cold-chain logistics	4–6 weeks, with frequent reflex to NGS for inconclusive results
Clinical Actionability	Comprehensive ACMG/AMP classified report integrated with genetic counseling recommendations and DHA-compliant interpretation	Fragmented results often requiring additional testing to guide management

Physician Insight & Safety Protocols

Consultant Medical Genetics Lina Osama Zaki Quteineh (DHA Registration ID: 9294403) shares: “Genetic testing for MRE11A variants provides critical insights for families navigating primary microcephaly and related disorders. Each result must be contextualized within the full clinical presentation, family history, and developmental trajectory of the patient. I emphasize the importance of pre-test counseling and post-test multidisciplinary follow-up to ensure that every finding translates into meaningful care.”

Medication Advisory

Important: Continue all prescribed therapies unless explicitly advised otherwise by your treating physician. Genetic test results should inform, not replace, ongoing clinical management. Always consult your doctor before making any changes to medications or treatment plans.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria: Non-consenting individuals; patients with active severe systemic infection or immunodeficiency where blood draw poses excessive risk; samples with confirmed DNA degradation after quality control; inability to provide a complete three-generation family pedigree for accurate interpretation.
Emergency Red Flags: If the patient experiences sudden neurological deterioration, new-onset seizures, progressive loss of consciousness, or signs of raised intracranial pressure (vomiting, lethargy, bulging fontanelle in infants) before or after sample collection, seek immediate emergency medical attention and postpone elective genetic testing until the patient is stabilized.

Patient FAQ & Clinical Guidance

1. What conditions does the MRE11 gene test detect?

This test identifies pathogenic variants in MRE11A linked to primary microcephaly, ataxia-telangiectasia-like disorder, and hereditary breast and ovarian cancer predisposition. A comprehensive report provides clarity for diagnosis, management, and family planning.

2. Is pre-test genetic counseling mandatory?

Yes, a thorough session with a DHA-licensed genetic counselor is required to construct a three-generation pedigree and obtain informed consent prior to testing. This ensures that every patient understands the scope, limitations, and implications of the results.

3. How is the sample collected and what is the turnaround time?

A peripheral whole blood sample is collected via painless venipuncture through our ISO-certified VIP mobile phlebotomy service available from 8 AM to 11 PM. Results are reported within 3 to 4 weeks from sample receipt.

4. Will insurance cover the cost of this test?

We provide direct billing verification for eligible insurance plans. Please contact our billing team via WhatsApp at +971 54 548 8731 to confirm coverage and any applicable co-payments.

UAE Regulatory & Data Privacy Adherence

All genetic testing services at DNA Labs UAE are conducted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data is encrypted, access-controlled, and processed exclusively within accredited laboratory environments to ensure the highest standards of confidentiality and regulatory compliance.

Clinical & Logistical Metadata

Test Name	MRE11 Gene (MRE11A) Microcephaly Genetic Test
Price (AED)	2,800 AED
Turnaround Time	21–28 Days (3–4 Weeks)
Sample Type / Matrix	Peripheral Whole Blood or Extracted DNA
Methodology Used	Next-Generation Sequencing (NGS) – Full Gene Sequencing with CNV Detection
ICD-10-CM Code	Q02 (Primary microcephaly)
LOINC Code	21636-6
DHA Facility License & Laboratory Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE